Orbimed Advisors LLC bought $14M of UPB
director, owner at Upstream Bio, Inc.. 825,000 shares at an average of $17.00, traded Oct 15, 2024, filed Oct 17, 2024.
Score components
- +15RoleDirector
- +25Trade size$14.0M at market
- +10Relative to holdingsHoldings up 85%
- 0Price contextNo price history yet
- +15Cluster3 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +7.9%, 3m -53.9%, 6m -62.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000947871-24-000806, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 15, 2024 | CConversion Common Stockindirect: See Footnote | +721,956 | - | - | 973,716 | Oct 17, 2024 |
| Oct 15, 2024 | POpen-market purchase Common Stockindirect: See Footnote | +165,000 | $17.00 | $2.8M | 1,138,716 | Oct 17, 2024 |
| Oct 15, 2024 | CConversion Common Stockindirect: See Footnote | +2,887,833 | - | - | 3,894,873 | Oct 17, 2024 |
| Oct 15, 2024 | POpen-market purchase Common Stockindirect: See Footnote | +660,000 | $17.00 | $11M | 4,554,873 | Oct 17, 2024 |
| Oct 15, 2024 | CConversion Series A redeemable convertible preferred stockderivativeindirect: See Footnote | -524,500 | - | - | 0 | Oct 17, 2024 |
| Oct 15, 2024 | CConversion Series A redeemable convertible preferred stockderivativeindirect: See Footnote | -2,098,000 | - | - | 0 | Oct 17, 2024 |
| Oct 15, 2024 | CConversion Series B redeemable convertible preferred stockderivativeindirect: See Footnote | -197,456 | - | - | 0 | Oct 17, 2024 |
| Oct 15, 2024 | CConversion Series B redeemable convertible preferred stockderivativeindirect: See Footnote | -789,833 | - | - | 0 | Oct 17, 2024 |
Related signals
Other insiders at Upstream Bio, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Upstream Bio, Inc. | Allison Ambrose General Counsel | $2,663 485 shares | -3% | |
| 30Weak | Upstream Bio, Inc. | Aaron Deykin Chief Medical Officer | $4,914 895 shares | -3% | |
| 37Weak | Upstream Bio, Inc. | Michael Gray CFO and COO | $4,683 853 shares | -3% | |
| 30Weak | Upstream Bio, Inc. | Adam Houghton Chief Business Officer | $3,843 700 shares | -3% | |
| 40Moderate | Upstream Bio, Inc. | Everett Rand Sutherland Chief Executive Officer | $12k 2,095 shares | -3% | |
| 40Moderate | Upstream Bio, Inc. | AI Upstream LLC owner | $20M 1,175,000 shares | - | |
| 65Notable | Upstream Bio, Inc. | Erez Chimovits director, owner | $14M 825,000 shares | +85% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.